Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Concept/Terms
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Antineoplastic Drug Resistance
- Drug Resistance, Antineoplastic
- Resistance, Antineoplastic Drug
- Resistance, Antineoplastic Agent
- Antineoplastic Agent Resistance
- Neoplasm Drug Resistance
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in Harvard Catalyst Profiles by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 4 | 5 |
1996 | 1 | 3 | 4 |
1997 | 1 | 2 | 3 |
1998 | 5 | 4 | 9 |
1999 | 0 | 9 | 9 |
2000 | 2 | 6 | 8 |
2001 | 2 | 15 | 17 |
2002 | 9 | 17 | 26 |
2003 | 14 | 18 | 32 |
2004 | 12 | 28 | 40 |
2005 | 14 | 36 | 50 |
2006 | 14 | 36 | 50 |
2007 | 23 | 45 | 68 |
2008 | 33 | 35 | 68 |
2009 | 32 | 51 | 83 |
2010 | 47 | 49 | 96 |
2011 | 48 | 45 | 93 |
2012 | 42 | 66 | 108 |
2013 | 55 | 66 | 121 |
2014 | 75 | 79 | 154 |
2015 | 101 | 66 | 167 |
2016 | 104 | 86 | 190 |
2017 | 83 | 106 | 189 |
2018 | 90 | 97 | 187 |
2019 | 84 | 102 | 186 |
2020 | 87 | 100 | 187 |
2021 | 71 | 77 | 148 |
2022 | 9 | 36 | 45 |
2023 | 6 | 43 | 49 |
2024 | 15 | 29 | 44 |
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer. Nat Commun. 2024 Jul 03; 15(1):5597.
-
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024 Jul 01; 109(7):2239-2249.
-
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. Haematologica. 2024 Jul 01; 109(7):2331-2336.
-
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL. Blood Adv. 2024 Jun 25; 8(12):3226-3236.
-
ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma. Nat Commun. 2024 Jun 21; 15(1):5294.
-
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma. Blood. 2024 Jun 20; 143(25):2612-2626.
-
Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024 Jun 11; 8(11):2952-2959.
-
Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue. Cancer Cell. 2024 Jun 10; 42(6):943-945.
-
High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2024 Jun 10; 12(6).
-
Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease. Cancer Discov. 2024 Jun 03; 14(6):915-919.